Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes

Documents similaires

• Review article: Evaluation and care of the critically ill patient with cirrhosis
  par: Iva Kosuta, et autres
  Publié: (2024)
• Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
  par: Nobuharu Tamaki, et autres
  Publié: (2024)
• Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
  par: Nabil Noureddin, et autres
  Publié: (2024)
• Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
  par: Aakash Desai, et autres
  Publié: (2024)
• Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
  par: Yewan Park, et autres
  Publié: (2024)